Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional) | PAR 20 269

Frequently Asked Questions (FAQs)

What is the NIH funding opportunity PAR-20-269?

PAR-20-269 is a National Institutes of Health (NIH) grant opportunity titled "Integrative Research to Understand the Impact of Sex Differences on the Molecular Determinants of AD Risk and Responsiveness to Treatment (R01 Clinical Trial Optional)." It supports research that explains, in a mechanistic and integrated way, how biological sex influences Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD).

What is the main purpose of this FOA?

The purpose is to move beyond simply documenting that males and females differ in AD/ADRD risk, symptoms, or outcomes. NIH is looking for research that uncovers the molecular and biological drivers of those sex differences across the full trajectory of brain aging, from aging patterns to clinical phenotypes and eventual AD/ADRD risk.

What does NIH mean by "integrative" research in this announcement?

"Integrative" means connecting multiple levels of evidence and expertise to explain sex-linked variability. Projects are expected to link mechanisms (such as molecular pathways, cellular processes, genetics, endocrinology, immunology, and brain systems) to observable outcomes like brain aging patterns, clinical phenotypes, and AD/ADRD risk.

What does "mechanistic" research mean in this FOA?

Mechanistic research is expected to identify causal pathways or clearly defined biological processes that account for sex differences. The FOA emphasizes going beyond describing associations and instead aiming to explain how and why sex differences occur at a biological and molecular level.

Is this opportunity focused only on sex differences in disease risk, or also on symptoms and progression?

It is focused on the full trajectory of brain aging and AD/ADRD, which can include differences in aging patterns, clinical phenotypes, disease onset, and progression. The key requirement is that the work explains the underlying molecular/biological drivers of those differences.

How does precision medicine fit into this funding opportunity?

A major emphasis is precision medicine: understanding whether and why prevention strategies and treatments work differently in males and females. The intent is to generate findings that support more targeted, sex-informed approaches to prevention and treatment.

What kinds of interventions can be studied for sex differences in treatment response?

The FOA includes responsiveness to both pharmacologic interventions (drugs, biologics, therapeutic agents) and non-pharmacologic interventions (such as lifestyle, behavioral, cognitive, or other non-drug approaches), as long as the project is mechanistic and integrative.

What NIH grant mechanism is used for PAR-20-269?

This opportunity uses the NIH R01 research project grant mechanism.

Are clinical trials required?

No. This FOA is "Clinical Trial Optional," meaning applicants may propose studies that include a clinical trial component if scientifically justified, but a clinical trial is not required.

What is the funding activity category and CFDA number?

The funding activity category is health, and the associated CFDA number is 93.866.

What is the award ceiling for this opportunity?

The listed award ceiling is $750,000.

When was this FOA created and what was the original closing date?

The FOA was created on July 17, 2020, and the original closing date was July 24, 2020.

Who is eligible to apply?

Eligibility is broad and includes many types of U.S. organizations and governments, including state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations and tribal governments that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education when applicable); for-profit organizations other than small businesses; and small businesses.

Are minority-serving institutions specifically mentioned as eligible?

Yes. NIH explicitly lists eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).

Are faith-based and community-based organizations eligible?

Yes. Faith-based or community-based organizations are explicitly listed among eligible applicant categories.

Are federal agencies eligible to apply?

Yes. Eligible federal government agencies are listed among the eligible applicant categories.

Can organizations in U.S. territories or possessions apply?

Yes. U.S. territories or possessions are explicitly listed among eligible applicant categories.

Are foreign (non-U.S.) organizations eligible?

Yes. Non-U.S. entities (foreign organizations) are explicitly listed as eligible applicants.

What types of research teams does NIH want to see for this FOA?

NIH is looking for cross-disciplinary, team-based applications that bring together complementary expertise and can connect biological mechanisms to clinically meaningful outcomes related to AD/ADRD risk, brain aging, and treatment responsiveness.

What would a strong-fit application generally look like based on the FOA description?

The strongest-fit projects would typically link biological mechanisms to clinically meaningful outcomes and be structured to produce findings that can guide future therapeutic development, intervention tailoring, or improved prediction of who is at risk and who is likely to benefit from specific interventions, with an explicit focus on sex-linked drivers of variability.